High expression of cell adhesion molecule 2 unfavorably impacts survival in non-small cell lung cancer patients with brain metastases
| Autor: | Lu Dai, Concetta Elisa Onesti, Ying-Ying Liang, Alfredo Addeo, Hui-Dong Long, Gang Chen, Pieter E. Postmus, Jun Yin, Zhi-Wei Liao, Yi-Hua Li, Justin D. Blasberg, Xu-Guang Rao, Jian Zhao |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine Oncology medicine.medical_specialty cell adhesion molecule 2 (CADM2) non-small cell lung cancer (NSCLC) Non-small cell lung cancer (NSCLC) CELL ADHESION MOLECULE 2 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Risk factor Lung cancer business.industry Cancer medicine.disease Primary tumor 030104 developmental biology risk factor 030220 oncology & carcinogenesis T-stage Cox analyses Original Article prognosis business Brain metastasis |
| Zdroj: | J Thorac Dis Journal of Thoracic Disease, 13(4), 2437-2446. AME PUBL CO |
| Popis: | BACKGROUND: Lung cancer is one kind of malignant tumor with a high risk for morbidity and mortality compared to other solid organ malignancies. Brain metastases occur in 30–55% of non-small cell lung cancer (NSCLC) patients. Prognosis of NSCLC patients with brain metastases is very poor. Our previous study showed that cell adhesion molecule 2 (CADM2) could regulate the development of brain metastasis in NSCLC cells. Therefore, the objective of the study is to evaluate the effect of CADM2 on the prognosis of NSCLC patients with brain metastases. METHODS: The expression of CADM2 was detected by quantitative real-time polymerase chain reaction (qRT-PCR) in the tissue of the primary tumor. Patients were followed up and overall survival (OS) was calculated. The relationships between CADM2 and clinicopathological features were analyzed using the chi-square test. Kaplan-Meier analysis was carried out to demonstrate the influence of CADM2 on the OS of patients. Univariate and multivariate Cox analyses were used to determine the prognosis of NSCLC patients with brain metastases. RESULTS: A total of 139 NSCLC patients with brain metastases from the Affiliated Cancer Hospital & Institute of Guangzhou Medical University, treated between January 2015 and December 2017 were evaluated retrospectively. The expression level of CADM2 in patients ranged from 1 to 17.2677, with a median of 6.0772. Chi-square analysis showed that CADM2 gene expression level was not significantly associated with gender, age, tumor location, histological subtype, tumor T stage, extracranial metastasis, or smoking status. However, CADM2 expression was notably associated with risk for lymph node metastasis. The results of the Kaplan-Meier analysis showed that high expression [CADM2 messenger RNA (mRNA) ≥6.0772] of CADM2 was markedly associated with poor prognosis. Univariate and multivariate Cox analyses demonstrated that CADM2 was an independent risk factor for survival in NSCLC patients with brain metastases (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|